James Berenson, MD¹, Alan Cartmell^2*, Roger Lyons³, Wael Harb⁴, Dimitrios Tzachanis^5*, Richy Agajanian^6*, Ralph V. Boccia, MD⁷, Morton Coleman⁸, Robert A. Moss, MD⁹, Robert M. Rifkin¹⁰, Marco Schupp^11*, Sandra Dixon^11*, Ying Ou^11*, Janet Anderl^11* and Jesus G. Berdeja, MD¹²

¹Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
²Comprehensive Blood and Cancer Center, Bakersfield, CA
³US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX
⁴Horizon Oncology Center, Lafayette, IN
⁵Cedars-Sinai Medical Center, Los Angeles, CA
⁶The Oncology Institute of Hope and Innovation, Downey, CA
⁷The Center for Cancer and Blood Disorders, Bethesda, MD
⁸NewYork-Presbyterian/Weill Cornell, New York, NY
⁹Robert A Moss MD Inc., Fountain Valley, CA
¹⁰US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO
¹¹Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
¹²Sarah Cannon Research Institute, Nashville, TN

Karthik Ramasamy^1*, Meletios A. Dimopoulos², Niels W.C.J. van de Donk³, Barbara Gamberi^4*, Frank Bridoux^5*, Matthew Streetly⁶, Elisabeth Kueenburg^7*, Barbara Rosettani^7*, Shona Collins^7*, Frederik Lersch^7*, Pamela Bacon^8*, Katja C. Weisel^9* and Pieter Sonneveld, MD, PhD¹⁰

¹Oxford University Hospitals NHS Trust, Oxford, United Kingdom, Oxford, United Kingdom
²National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
³Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
⁴Arcispedale S. Maria Nuova, Reggio Emilia, Italy
⁵University Hospital and University of Poitiers, Poitiers, France
⁶Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom
⁷Celgene International, Boudry, Switzerland
⁸Celgene International Sàrl, Boudry, Switzerland
⁹Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany
¹⁰Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Peter M. Voorhees, MD¹, Flora Mulkey^2*, Hani Hassoun, MD³, Claudia E. Paba-Prada, MD⁴, Yvonne A. Efebera, MD, MPH⁵, Eva Hoke^2*, Guadalupe Aquino^6*, Destin Carlisle^7*, Vera Suman^8* and Paul G. Richardson, MD⁹

¹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
²Alliance Statistics and Data Center, Durham, NC
³Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Comprehensive Cancer Center, The Ohio State University, Columbus, OH
⁶National Institute of Neurological Disorders and Stroke, Office of Clinical Research, NIH, Bethesda, MD
⁷Alliance Protocol Operations Office, University of Chicago, Chicago, IL
⁸Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
⁹Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Jatin J. Shah, MD¹, Lei Feng, MS^2*, Sheeba K. Thomas, MD³, Donna Weber, MD³, Michael Wang, MD⁴, Elisabet E. Manasanch, MD³, Kathleen Mendoza, RN^3* and Robert Z. Orlowski, Ph.D., M.D.⁴

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Ajai Chari, MD^1*, Saurabh Chhabra, MD^2*, Saad Usmani, MD³, Sarah Larson, MD⁴, Ruben Niesvizky, MD^5*, Jeffrey Matous, MD⁶, Cristina Gasparetto, MD⁷, Beata Holkova, MD⁸, Matthew Lunning, DO⁹, Jason Valent, MD^10*, Larry D. Anderson Jr., MD, PhD¹¹, Chatchada Karanes, MD^12*, Long Kwei, PhD^13*, Lipo Chang^13*, Thorsten Graef, MD, PhD^13*, Elizabeth Bilotti, MSN^13* and Kevin McDonagh, MD^14*

¹Icahn School of Medicine at Mount Sinai, New York, NY
²Medical University of South Carolina, Charleston, SC
³Levine Cancer Institute/Carolinas Healthcare System,, Charlotte, NC
⁴University of California, Los Angeles, CA
⁵Weill Cornell Medical College, New York, NY
⁶Colorado Blood Cancer Institute, Denver, CO
⁷Duke University Medical Center, Durham, NC
⁸Virginia Commonwealth University Medical Center, Richmond, VA
⁹Virginia Commonwealth University Medical Center, Omaha, NE
¹⁰Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
¹¹University of Texas Southwestern Medical Center, Dallas, TX
¹²City of Hope National Medical Center, Duarte, CA
¹³Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁴Vanderbilt-Ingram Cancer Center, Nashville, TN

Jatin Shah^1*, Ruben Niesvizky, MD², Edward Stadtmauer^3*, Robert M. Rifkin⁴, James Berenson, MD⁵, Jesus G. Berdeja, MD⁶, Jeff P. Sharman, MD⁷, Roger Lyons⁸, Zandra Klippel, MD⁹, Hansen Wong^9*, Yu-Lin Chang^9* and Saad Usmani^10*

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
³University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
⁴US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO
⁵Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
⁶Sarah Cannon Research Institute, Nashville, TN
⁷US Oncology Network/Willamette Valley Cancer Institute, Springfield, OR
⁸US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX
⁹Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
¹⁰Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC